Change in Weight Loss Compared to Baseline
Primary
· Baseline and 12 weeks
The weight assessed by a body scale
| Group | Value | 95% CI |
|---|---|---|
| Experimental Group | -2.6 | ± 0.9 |
| Inulin | -3 | ± 1.04 |
Last reviewed · How we verify
NCT03322514: ProAp
Colonic Propionate, Appetite, and Weight Loss
Completed
NA
Results posted
Last updated 20 November 2019
What this trial tests
NA trial testing Inulin-Propionate Esters in Healthy Obesity, Metabolically in 12 participants. Completed in 11 November 2017.
Timeline
29 March 2017
Primary endpoint
11 November 2017
11 November 2017
11 November 2017
Quick facts
| Lead sponsor | Imperial College London |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 12 |
| Start date | 29 March 2017 |
| Primary completion | 11 November 2017 |
| Estimated completion | 11 November 2017 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Inulin-Propionate Esters
- Inulin — full drug profile →
Conditions studied
- Healthy Obesity, Metabolically — all drugs for Healthy Obesity, Metabolically →
- Appetite Regulation — all drugs for Appetite Regulation →
Sponsor
Imperial College London
Who can join
Adults 18 to 65, any sex, with Healthy Obesity, Metabolically or Appetite Regulation. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Glucose Blood Level Baseline to 12 Weeks
Secondary
· Baseline, 12 weeks
Baseline
| Group | Value | 95% CI |
|---|---|---|
| Experimental Group | 4.9 | ± 0.1 |
| Inulin | 4.4 | ± 0.1 |
12 weeks
| Group | Value | 95% CI |
|---|---|---|
| Experimental Group | 5.1 | ± 0.1 |
| Inulin | 4.8 | ± 0.1 |
Insulin Level in Serum
Secondary
· Baseline, 12 weeks
Baseline
| Group | Value | 95% CI |
|---|---|---|
| Experimental Group | 50.4 | ± 10.8 |
| Inulin | 48.9 | ± 18.3 |
12 weeks
| Group | Value | 95% CI |
|---|---|---|
| Experimental Group | 41.0 | ± 6.7 |
| Inulin | 46.0 | ± 21.1 |
Sponsor's own description
The current protocol aims to investigate the impact of the propionate ester in conjugation with restricted diet on appetite and weight loss.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches.
Williams LM, Cao S. · · 2024 · cited 13× · PMID 38367866 · DOI 10.1016/j.pharmthera.2024.108605
Verify or expand the search:
- PubMed search for NCT03322514
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy Obesity, Metabolically
Currently open trials in the same condition.
- NCT06799897 — Natural Course of Initially Metabolic Healthy Obese Individuals (Healthy Obesity)? · recruiting
- NCT05191160 — The Soy Treatment Evaluation for Metabolic Health (STEM) Trial · NA · active not recruiting
Other Imperial College London trials
Trials by the same sponsor.
- NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
- NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
- NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
- NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
- NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03322514 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Imperial College London
- Last refreshed: 20 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03322514.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing